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Chemokine receptor CXCR4 plays an important role
in the immune system and the cellular entry of human
immunodeficiency virus type 1 (HIV-1). To probe the
stereospecificity of the CXCR4-ligand interface, D-amino
acid peptides derived from natural chemokines, viral
macrophage inflammatory protein II (vMIP-II) and stromal cell-derived factor-1␣ (SDF-1␣), were synthesized
and found to compete with 125I-SDF-1␣ and monoclonal
antibody 12G5 binding to CXCR4 with potency and selectivity comparable with or higher than their L-peptide
counterparts. This was surprising because of the profoundly different side chain topologies between D- and
L-enantiomers, which circular dichroism spectroscopy
showed adopt mirror image conformations. Further direct binding experiments using D-peptide labeled with
fluorescein (designated as FAM-DV1) demonstrated that
D- and L-peptides shared similar or at least overlapping
binding site(s) on the CXCR4 receptor. Structure-activity analyses of related peptide analogs of mixed chiralities or containing alanine replacements revealed specific residues at the N-terminal half of the peptides as
key binding determinants. Acting as CXCR4 antagonists
and with much higher biological stability than L-counterparts, the D-peptides showed significant activity in
inhibiting the replication of CXCR4-dependent HIV-1
strains. These results show the remarkable stereochemical flexibility of the CXCR4-peptide interface. Further
studies to understand the mechanism of this unusual
feature of the CXCR4 binding surface might aid the development of novel CXCR4-binding molecules like the
D-peptides that have high affinity and stability.
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tion, CXCR4 together with another chemokine receptor CCR5
are two principal co-receptors for the cellular entry of the
human immunodeficiency virus type 1 (HIV-1)1 (4 –7). The
stromal cell-derived factor-1 (SDF-1␣) is the only known natural ligand of CXCR4 and plays important roles in migration,
proliferation, and differentiation of leukocytes (8, 9). The viral
macrophage inflammatory protein II (vMIP-II) encoded by human herpesvirus 8 (10) is an antagonistic chemokine ligand of
CXCR4 (11, 12). vMIP-II also interacts with other chemokine
receptors such as CCR5 and CCR3 and inhibits HIV-1 entry
mediated by these co-receptors.
CXCR4 and other chemokine receptors belong to the superfamily of seven transmembrane G-protein-coupled receptors
(GPCRs) (13). These membrane proteins transmit signals from
extracellular ligands to intracellular biological pathways via
heterotrimeric G-proteins and have been a major class of therapeutic targets for a wide variety of human diseases (14). As
such, characterizing the mechanism of biological recognition
between these receptors and their ligands is essential for understanding the physiological or pathological processes that
they mediate and devising novel strategies for clinical intervention. For CXCR4, studies have been carried out by a number of laboratories using chimeric chemokine receptors and
site-specific mutants to study multiple domains of CXCR4 that
are important for interacting with chemokine ligands and
HIV-1 (15–23). However, because there is no high resolution
crystal structure available for CXCR4 (or any other chemokine
receptor) alone or complexed with ligands, the structural and
biochemical basis of ligand binding and signaling through
these important membrane receptors remains poorly
understood.
To further define the structure-function relationship of the
chemokine receptor-ligand interaction, theoretical computer
modeling and site-directed mutagenesis were combined to predict plausible structural models for chemokine receptors and
their complexes with ligands, such as interleukin-8 receptor ␤
(24) and CCR5 (25, 26). Structural models of CXCR4 and its
complex with ligands were also proposed (27, 28). Complementary to modeling and mutational analyses of the receptors,
1
The abbreviations used are: HIV, human immunodeficiency virus;
SDF, stromal cell-derived factor; vMIP, viral macrophage inflammatory
protein; MIP, macrophage inflammatory protein; GPCR, G-protein-coupled receptor; Fmoc, N-(9-fluorenyl)methoxycarbonyl; DMF, N,Ndimethylformamide; CAT, chloramphenicol acetyltransferase; PBS,
phosphate-buffered saline; mAb, monoclonal antibody; PBMC, peripheral blood mononuclear cell; HPLC, high performance liquid
chromatography.
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chemical synthetic approach was used to dissect the structural
and functional determinants of a number of chemokines and
their binding to receptors (29). As to chemokines SDF-1␣ and
vMIP-II, which recognize CXCR4, a large number of synthetic
mutants and peptide analogs of SDF-1␣ were used to analyze
the structure-activity relationship of different regions of
SDF-1␣ in CXCR4 binding (30 –34).
For vMIP-II, we recently found that a synthetic 21-residue
peptide derived from the N terminus of vMIP-II, designated as
V1, is a potent antagonist of CXCR4 and inhibits HIV-1 replication in CXCR4⫹ T-cell lines (35, 36). Being highly amenable
to chemical synthesis and modification, this V1 peptide
prompted us to use chemically modified analogs of V1 as probes
to study the molecular recognition of CXCR4-ligand complex.
Because one important aspect of receptor-ligand interaction is
the requirement of stereospecificity, we report here the synthesis and structure-function characterization of all-D-amino acid
analogs of V1 peptide, designated DV1 peptides. Unexpectedly,
these D-peptides display strong binding and antagonistic activity toward CXCR4, thus revealing that the peptide binding site
on CXCR4 is tolerant of changes in chirality of ligands. Similar
observations are also made for other D-peptides derived from
the N terminus of SDF-1␣. These findings have important
implications for understanding the mechanism of CXCR4-ligand interaction and designing novel inhibitory molecules.
Furthermore, DV1 peptides are highly resistant to proteolytic
degradation and show significant activity in blocking HIV-1
replication in CXCR4⫹ cell lines, thus demonstrating their
advantage over natural L-peptides for potential clinical
application.
EXPERIMENTAL PROCEDURES

Materials—Recombinant human chemokines SDF-1␣, MIP-1␤, and
vMIP-II (R&D Systems, Minneapolis, MN) were lyophilized and dissolved as 1 or 2.5 g/l stock solutions in sterile phosphate-buffered
saline (PBS) and stored at ⫺20 °C in aliquots. The radioiodinated
MIP-1␤ and SDF-1␣ were purchased from PerkinElmer Life Sciences.
The specific activity of 125I-MIP-1␤ and 125I-SDF-1␣ was 2200 Ci/mmol.
Cell culture media and G418 were purchased from Invitrogen. The
anti-CXCR4 monoclonal antibody (mAb) 12G5 (37) was purchased from
BD PharMingen (San Diego, CA). 293 cells (gift from Dr. R. Doms,
University of Pennsylvania) and Sup-T1 cells (provided by the National
Institutes of Health AIDS Reagent Program) were maintained in Dulbecco’s modified Eagle’s medium plus 10% fetal bovine serum. The cell
lines used for the HIV-1 replication assay were kindly provided by other
laboratories: MT-4 cells by Dr. N. Yamamoto (Tokyo Medical and Dental University, Tokyo, Japan), chronically HIV-1-infected H9 cells (H9/
IIIB) by the National Institutes of Health AIDS Research and Reference
Reagent Program, and Sup-T1 cells by Dr. J. Hoxie (University of
Pennsylvania). These cells were grown in 25 mM HEPES-buffered
RPMI 1640 supplemented with 10% fetal bovine serum, 50 units/ml
penicillin, 50 g/ml streptomycin, and 0.125 g/ml amphotericin B.
HIV-1 was prepared from a culture supernatant of H9/IIIB cells.
Peptide Synthesis—The peptides were prepared by solid phase synthesis using N-(9-fluorenyl)methoxycarbonyl (Fmoc) strategy on a 430A
peptide synthesizer (Applied Biosystems, Foster City, CA) and a 9050
Pepsynthesizer Plus (Perseptive Biosystems, Cambridge, MA), as described previously (38, 39). The side chain protecting groups of N␣-Fmoc
amino acids were: Arg, 2,2,5,7,8-pentamethyl-chroman-6-sulfonyl; Asp,
tert-butyl ester; Cys, trityl; Gln, trityl; His, trityl; Lys, tert-butyloxycarbonyl; Ser, tert-butyl ester, Tyr, tert-butyl ester; and Trp, tert-butyloxycarbonyl. In every coupling reaction step, a 4-fold excess of N␣-Fmoc
amino acid, O-benzotriazol-1-yl-N,N,N⬘,N⬘-tetramethyluronium hexafluorophosphate, and 1-hydroxybenzotriazole, and 10-fold excess of diisopropylethylamine were used. The cleavage of peptides from the resin
was carried out with the cleavage reagent (trifluoroacetic acid/thioanisole/phenol/water/ethanedithiol/triisopropylsilane, 81.5:5:5:5:2.5:1) for
2 h at room temperature with gentle stirring. Crude peptides were
precipitated in ice-cold methyl-t-butyl ether, centrifuged, and lyophilized. The crude peptides were then purified by preparative HPLC using
a Dynamax 300-Å C18 column (25 cm ⫻ 21.4 mm, inner diameter) with
two solvent systems of 0.1% trifluoroacetic acid/H2O and 0.1% trifluoroacetic acid/acetonitrile. Fractions containing the appropriate peptide
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were pooled together and lyophilized. The purity of the final product
was assessed by analytical reverse phase high performance liquid chromatography, capillary electrophoresis, and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. All peptides were
at least 95% pure.
To prepare FAM-DV1, a DV1 peptide labeled with fluorescein (coupled to the NH2 group of the side chain of K-17 of DV1 sequence), the
K-17 side chain was protected with (4,4-dimethyl-2,6-dioxocyclohex-1ylidene)ethyl and the N-terminal leucine was N-protected with tertbutyloxycarbonyl. The (4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethyl
group was removed at the end of the synthesis from the DV1 peptideresin utilizing 2% hydrazine in DMF (3 min at room temperature, three
times). The resin was then washed with DMF and treated at room
temperature with 5-carboxylfluorescein (2.5 eq), 2-(1H-benzotriazole-1yl)-1,1,3,3-tetramethylaronium hexafluorophosphate (HBTU) (2.5 eq),
N-hydroxybenzotriazole (HOBt) (2.5 eq), and diisopropylethylamine
(DIEA) (5 eq) in DMF (minimum to cover the resin) overnight. When
necessary, the coupling was repeated to obtain a negative Kaiser test.
The resin was finally washed with DMF and dichloromethane, cleaved
and purified as described above.
CD Spectroscopy—The experiments were performed following our
previously published procedure (24, 40). 50 M solutions of peptides
were prepared in 0.01 M sodium phosphate buffer. The spectra were
recorded on an Aviv 62A DS spectrometer (Aviv Instruments Inc.,
Lakewood, NJ) with a 0.01-cm path length quartz cuvette and scanned
by every 2 nm at room temperature.
Flow Cytometry—Following the procedure described in our recent
publication (35), Sup T1 cells (2 ⫻ 105) were incubated with an antiCXCR4 monoclonal antibody (mAb) 12G5 (10 g/ml) and various concentrations of peptides for 40 min at 4 °C, then with fluorescein isothiocyanate-conjugated goat anti-mouse IgG (Southern Biotechnology
Associates, Inc., Birmingham, AL) for 40 min at 4 °C. Finally the cells
were fixed in 2% paraformaldehyde in PBS and analyzed on a FACScan
flow cytometer (Coulter Epics Elite, Beckman Coulter, Hialeah, FL).
12G5 Competitive Binding to CXCR4 —Sup-T1 cells were incubated
with anti-CXCR4 mAb 12G5 (10 g/ml) in the presence of different
concentrations of the peptide at 4 °C for 40 min. The cells were washed
twice with the binding buffer and stained with fluorescein isothiocyanate-labeled secondary antibody at 4 °C for another 40 min. Finally, the
cells were washed two to three times and fixed with the fixing buffer. As
a negative control, cells were stained only with secondary antibody. The
final data points were taken as the mean fluorescence intensity of the
peptide sample subtracted by that of the control. The IC50 values of the
peptides in competing with 12G5 binding to CXCR4 were calculated by
using Prizm software.
125
I-SDF-1␣ Competitive Binding to CXCR4 —CEM-T4 cells were
harvested and washed twice with PBS. Competition binding experiments were performed using a single concentration (0.2 nM) of 125ISDF-1␣ in the presence of increasing concentrations of unlabeled ligands in a final volume of 100 l of binding buffer (50 mM HEPES, pH
7.4, 1 mM CaCl2, 5 mM MgCl2, 0.1% bovine serum albumin) containing
2 ⫻ 105 cells. Nonspecific binding was determined by the addition of 100
nM unlabeled SDF-1␣. Samples were incubated for 60 min at room
temperature. The incubation was terminated by separating the cells
from the binding buffer by centrifugation and washing once with 500 l
of cold binding buffer. Bound ligands were quantitated by counting ␥
emissions.
125
I-MIP-1␤ Competitive Binding to CCR5—Following an experimental procedure similar to that described above, 293 cells transfected with
CCR5 and 125I-MIP-1␤ were used to determine the specific binding
activity of peptides to CCR5.
FAM-DV1 Competitive Binding to CXCR4 —Sup-T1 cells were
washed twice with PBS (Ca2⫹- and Mg2⫹-free). Ligand binding experiments were preformed using FAM-DV1 (200 nM) with SDF-1␣ (300 nM),
DV1 (100 M), or V1 (100 M) in a final volume of 50 l of binding buffer
(50 mM HEPES, pH 7.4, 1 mM CaCl2, 5 mM MgCl2, 0.1% bovine serum
albumin) containing 2 ⫻ 106 cells. Samples were incubated for 30 min
at room temperature in the dark, followed by resuspension and another
30-min incubation. The incubation was terminated by separating the
cells from the binding buffer by centrifugation and washing twice with
200 l of cold binding buffer. After the final wash, 100 l of binding
buffer was added, and the cells were spun down for fluorescent analysis.
Bound ligands were determined by counting fluorescent emission at 535
nm wavelength with a 1-s time delay (Wallac Victor2 1420). At least
three independent experiments were performed. Nonspecific binding of
FAM-DV1 was determined by the addition of 100 M DV1 (500-fold in
excess of 200 nM FAM-DV1 used). The fluorescence with 200 nM of
FAM-DV1 only was scaled to yield 100% FAM-DV1 bound. Similarly,
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the fluorescence of each sample was adjusted to calculate the percentage of FAM-DV1 bound.
Intracellular Calcium Measurement—Sup T1 cells and CCR5 transfected 293 cells were used to measure the intracellular calcium influx.
[Ca2⫹]i was measured using excitation at 340 and 380 nm on a fluorescence spectrometer (PerkinElmer LS50). Calibration was performed
using 0.033% Triton X-100 for total fluorophore release and 1.66 mM
EGTA to chelate free Ca2⫹. Intracellular Ca2⫹ concentrations were
calculated by using the fluorescence spectrometer measurement
program.
Stability of Peptides in Human Serum—Pure human serum (kindly
provided by Robert Korngold, Thomas Jefferson University, Philadelphia, PA) was diluted with PBS to 80% serum solution. DV1 and V1
peptides were dissolved in the serum solution with a concentration of 10
mM. Samples were collected at different time points of incubation at
room temperature and subjected to HPLC analysis with the injection of
10-l peptide samples (Microsorb-MV C18 5-m, 25 cm ⫻ 4.6 mm, 80%
CH3CN with 0.1% trifluoroacetic acid, UV 220 nm, 1 ml/min). The
stability of the peptides was calculated based on the changes in the
intensity of UV absorbance of the peptides.
Virus Neutralization Assay—Recombinant viruses were generated
by cotransfecting the human 293 T cell line with pSVIIIenv plasmids
expressing either HXBc2 or 89.6 envelope glycoproteins and
pHXBH10⌬envCAT (41). Recombinant viruses were normalized for reverse transcriptase activity and used to infect the following target cells:
(i) human PBMC activated with phytohemagglutinin (PHA) and interleukin-2 or (ii) canine thymocytes expressing human CD4 or human
CD4 plus human CCR5 (42). The target cells were preincubated with
the peptides at varying concentration for 1 h prior to coculture with the
recombinant viruses. Infected cells were harvested 3 days later, and
CAT activity was measured in cell lysates, as previously described (43).
HIV-1-induced Cytopathic Effect and Viral p24 Antigen Production—As described previously (44), MT-4 cells were seeded at 6 ⫻ 104
cells/150 l/well in a 96-well microplate. HIV-1 was added at 50 TCID50/
well in the absence or presence of peptide inhibitors. After 4 days of
incubation at 37 °C in a CO2 incubator, the supernatant was examined
for the level of viral p24 antigen using the enzyme immunoassay kit
(Beckman Coulter). The cell viability was also determined by 3⬘-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide method. The cytotoxic effect of peptides on MT-4 cells was assessed by incubating
uninfected cells with peptides without the addition of HIV-1 under the
same conditions as above.
RESULTS
D-Peptides

Derived from vMIP-II N Terminus Bind
CXCR4 —In this study, we used synthetic all-D-amino acid
peptides to explore the stereospecificity of the molecular recognition between the CXCR4 receptor and its ligands. Based on
our previous finding that V1 peptide derived from the N terminus (residues 1–21) of viral chemokine vMIP-II antagonizes
CXCR4 function and blocks HIV-1 entry via CXCR4 (35, 36), we
synthesized DV1, an all-D-enantiomer of V1 peptide that has
the identical amino acid sequence as V1 but the chirality of all
residues changed to D-configuration (Table I). DV1 showed a
circular dichroism (CD) spectrum that is the mirror image of
V1 peptide (Fig. 1a). In addition, the spectra displayed negative
and positive intensity bands near 220 nm for V1 and DV1,
respectively, suggesting that both peptides adopted a random
conformation in aqueous solution. If DV1 and V1 are mirror
images of each other as suggested by CD, there is significant
conformational difference between them, as highlighted by distinct amino acid side chain orientations in their structural
models (Fig. 2).
DV1 peptide was tested for CXCR4 binding activity in a
competitive binding assay using anti-CXCR4 mAb 12G5 following the procedure described previously (35). Surprisingly, despite the changes in chirality of all amino acids and thus
extensive conformational difference from parent V1 peptide as
described above, DV1 peptide showed strong binding affinity
for CXCR4 (Fig. 3a). Furthermore, the CXCR4 binding affinity
of DV1 peptide was much higher than that of V1 peptide, as
shown by an IC50 of 32 nM for DV1 as compared with that of 456
nM for V1 in competing with the specific CXCR4 binding by

TABLE I
Peptide sequences and their activity in anti-CXCR4 mAb 12G5
competitive binding assay

a

Unless specified otherwise (for V1 and S1), all residues are of

D-configuration.
b

Those L-amino acid residues in the sequence are indicated by underlines, whereas the rest are D-amino acids.
c
The position for alanine replacement is indicated by bold and underlined type

mAb 12G5 (Table I). Using another assay method, DV1 was
shown to compete with 125I-SDF-1␣ in CXCR4 binding with an
IC50 of 13 nM as compared with that of 218 nM V1 peptide (Fig.
3b). Because vMIP-II binds other receptors such as CCR5, we
tested the activity of DV1 peptide in CCR5 binding using the
125
I-MIP-1␤ competitive binding method. In contrast to its
strong CXCR4 interaction, DV1 peptide did not show any CCR5
binding even at a much higher concentration of 100 M (Fig.
3c). Consistently, a similar observation was made for V1 peptide (35). These results suggested that CXCR4 binding by both
DV1 and V1 peptides appear to be receptor-selective.
To further demonstrate CXCR4 recognition by DV1 peptide,
a FAM-labeled DV1 peptide was prepared for conducting direct
ligand binding experiments on Sup T1 cells that naturally
express CXCR4 (Fig. 4). The binding of FAM-DV1 on Sup T1
cells was mediated by CXCR4, as shown by the significant
reduction of binding signal of FAM-DV1 upon the addition of
SDF-1␣. This was consistent with the results of DV1 in competing with 125I-SDF-1␣ in CXCR4 binding as described above
and further supported the hypothesis that DV1 peptide recognizes CXCR4 receptor. To examine whether D- and L-peptides
bind to similar or different site(s) on CXCR4, 100 M V1 peptide
was added and found to block FAM-DV1 binding, completely
similar to the effect of 100 M unlabeled DV1 peptide (Fig. 4).
These results indicated that these peptides of opposite chiralities recognize similar or at least overlapping site(s) on the
receptor. Again, this was consistent with the ability of both
peptides in competing with 125I-SDF-1␣ and mAb 12G5 in
CXCR4 binding as described above. Competitive binding studies using FAM-DV1 peptide were also conducted on 293 cells
transfected with wild type CXCR4. When 200 nM FAM-DV1
was used, there was significantly higher (⬃50%) FAM-DV1
binding to CXCR4 transfected 293 cells than 293 cells, whereas
the difference was much less for lower concentrations (100 and
200 nM) of FAM-DV1 (data not shown). This was probably a
result of the high nonspecific binding of FAM-DV1 to 293 cells,
which was also observed for 125I-SDF-1␣. Consistent with the
results obtained on Sup T1 cells, the binding of FAM-DV1 on
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FIG. 1. a, CD spectra of DV1 (f) and V1
(䡺) peptides. b, CD spectra of DV1 (f)
and mutant DV1-L1A (‚) peptides.

CXCR4-transfected 293 cells was inhibited by the addition of
SDF-1␣ (300 nM), DV1 (100 M), or V1 (100 M) (data not
shown).
N-terminal Half of D-Peptides Is the Major Determinant of
CXCR4 Binding—As described above, the chirality change in
all amino acid residues of V1 peptide resulted in DV1 peptide
with significantly increased CXCR4 affinity. To further explore
the effect of chirality on receptor binding, peptides of hybrid
chiralities were synthesized. By using Cys-11 as the central
point of V1 peptide, we changed the chirality of residues before
(residues 1–10) and after Cys-11 (residues 12–21) to D-configuration, respectively (Table I). Two peptides synthesized accordingly were therefore designated as V1-DCL and V1-LCD
that were composed of mixed D- and L-amino acids. V1-DCL
peptide has D-configuration for the N-terminal half and L-configuration for the C-terminal half, whereas V1-LCD peptide
has the opposite. Both peptides were subjected to anti-CXCR4
mAb 12G5 competitive binding assay. V1-DCL displayed
CXCR4 binding activity comparable with DV1, and a similar
observation was made for V1-LCD and V1 (Table I and Fig. 5a).
These results further confirmed the ability of CXCR4 in recognizing peptide ligands of opposite or mixed chiralities. In addition, they suggested that CXCR4 binding affinity of these
peptides was mainly determined by the chirality of their N-

terminal half with D-residues at this part interacting with
CXCR4 receptor better than L-residues. Apparently, the first 10
residues of DV1 or V1 are the major determinant of activity. In
contrast, chirality change in the C-terminal half had much less
effect on CXCR4 binding activity.
To further address the role of the C-terminal half, we synthesized a truncated DV1 analog, designated as DV3, in which
C-terminal residues (residues 11–21) of DV1 were removed.
Although retaining CXCR4 binding, DV3 was less potent than
DV1 (Table I and Fig. 5a). This is consistent with previous
study of V3 peptide, a truncated V1 analog that also contains
only first 10 residues and shows much decreased CXCR4 binding as compared with V1 (35). These results indicated that,
although the N-terminal half (residues 1–10) is most important, the C-terminal half (residues 11–21) also plays a role in
receptor binding.
Specific Residues in D-Peptides Important for CXCR4 Recognition—To further characterize the structure-activity relationship of DV1 peptide, eight mutant peptides containing alanine
replacement at various positions of DV1 were synthesized (Table I). Consistent with the important role of the N-terminal half
of DV1 peptide as discussed above, mutations in this part had
more significant effect on receptor binding than mutations in
the other part. Mutant peptides DV1-L1A, DV1-W5A, and
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FIG. 2. Different amino acid side chain conformations between
DV1 and V1 peptides. These models were randomly generated and
based on the assumption that the peptides adopt a mirror image structure, as shown by CD spectra. Note that, whereas all amino acid side
chains in these two peptides display different orientations because of
their opposite chiralities, only the side chains of Leu-1 and Trp-5 that
are shown by mutation studies to be critical for CXCR4 binding are
chosen as representatives and highlighted in black. Two views of DV1
peptide are shown: one as the mirror image of V1 peptide with opposite
peptide main chain and side chains and the other after 180° rotation
with the same main chain direction but different side chain
orientations.

DV1-R7A containing alanine substitutions at Leu-1, Tyr-5, and
Arg-7, respectively, all displayed a substantial loss of CXCR4
binding with a decrease in IC50 values of 34 –741-fold (Table I
and Fig. 5b). In contrast, mutations in the C-terminal half
(Cys-11, Cys-12, Gln-16, and Arg-18) led to little or less significant change in binding activity. To determine whether the
difference in receptor affinity of these mutant peptides were
the result of conformational changes induced by the mutations,
we studied the solution conformations of DV1-L1A that showed
the most dramatic change in CXCR4 binding by CD spectroscopy. DV1-L1A and DV1 displayed similar CD spectra, indicating no major conformational difference (Fig. 1b). As such,
changes in CXCR4 binding of mutant peptides were more likely
caused by the loss of specific side chains from the alanine
replacement and thus should reflect the role of these side
chains in receptor interactions.
Because both DV1 and V1 peptides recognize CXCR4 despite
their very different side chain orientations caused by changes
in chirality, this raised the question of whether these peptides
may bind the receptor through nonspecific interactions. A diverse group of peptides and organic molecules with a high
positive charge (⫹8 or ⫹9) are known to bind CXCR4, presumably through electrostatic interactions with the negatively
charged surface (⫺9) of CXCR4 (45– 48). It can be imagined
that these interactions are likely less sensitive to changes in
the stereochemistry of ligands so long as the overall positive
charge is maintained. However, this should not be the case for
DV1 peptide because it has an overall charge of only ⫹3.5,
much lower than other highly positively charged CXCR4 ligands described above. In addition, mutant peptides DV1K10A and DV1-R18A, in which positively charged side chains
of Lys-10 and Arg-18 were removed, respectively, have an even
lower charge of ⫹2.5, yet retain significant CXCR4 binding
activity. Most importantly, as discussed above for mutants
DV1-L1A and DV1-W5A, uncharged hydrophobic side chains
(most notably the side chain of Leu-1) of DV1 peptide play an
essential role in receptor recognition and are responsible for
different receptor affinities of up to 741-fold. A similar conclusion was drawn in previous analysis of V1 and mutant peptides

(36). Taken together, these data clearly demonstrated that,
despite the seemingly contradictory notion of the nonspecificity
of CXCR4 toward the stereochemistry of ligands, CXCR4 interacts with both DV1 and V1 peptides with a high degree of
sensitivity for specific side chain groups in these peptides.
Given that the orientations of side chains in DV1 and V1
peptides are not the same because of their different D- and
L-configurations (Fig. 2), one should expect that corresponding
residues in DV1 and V1 peptides have distinct interactions
with CXCR4 and thus contribute differently to receptor binding. To verify this, we compared the changes in receptor binding affinity caused by mutations in DV1 and V1 peptides (Table
II). The largest difference in residue contribution to receptor
binding between DV1 and V1 peptides was found for those
residues at the N-terminal half, e.g. Leu-1 was the most critical
binding determinant and Lys-10 the least important one for
DV1, whereas the corresponding Lys-10 was most critical for
V1. By contrast, the difference in residue contribution to
CXCR4 affinity between these two peptides was much smaller
for the C-terminal half, which was consistent with the less
important role of the C-terminal half in receptor recognition.
D-Peptides Derived from SDF-1␣ N Terminus Also Recognize
CXCR4 —Having shown that the peptide binding surface of
CXCR4 is tolerant of chirality changes in peptide ligands derived from the N terminus of vMIP-II, we wanted to test
whether this may also apply to other chemokine-derived peptides. A peptide derived from the N terminus (residues 5–14) of
SDF-1␣ has been shown previously to bind CXCR4 (31–33).
With different size and sequence from DV1 and V1 peptides,
this SDF-1␣ N-terminal peptide should allow us to test the
generality of our hypothesis. Both D- and L-enantiomers of this
peptide sequence were synthesized and designated as DS1 and
S1 peptides, respectively (Table I). Their different conformations as the mirror image of each other were confirmed by CD
spectra (data not shown). DS1 and S1 peptides showed similar
binding affinity for CXCR4 in anti-CXCR4 mAb 12G5 competitive binding assay (Fig. 5c). The ability of both peptides to
recognize CXCR4 was also verified by a different binding
method using 125I-SDF-1␣ (data not shown). These results
further supported the notion that CXCR4 receptor can accommodate the changes in amino acid chirality of different peptide
ligands.
D-Peptides Inhibit SDF-1␣ Signaling through CXCR4 —DV1
peptide was tested for activity in inducing signal via CXCR4 as
measured by intracellular calcium influx in Sup T1 cells expressing the receptor. DV1 did not show any activity in triggering CXCR4 signal transduction but blocked SDF-1␣ signaling via CXCR4, thus indicating that it is an antagonist of
CXCR4 function (Fig. 6). This is consistent with a previous
observation that V1 peptide is also a CXCR4 antagonist (35).
For those DV1 mutant peptides that had some binding activity
for CXCR4 (Table I), their ability to induce signal or interfere
with SDF-1␣ signaling via CXCR4 was also studied by using
the same assay. None of the mutant peptides tested showed
any signaling activity via CXCR4 and are thus receptor antagonists like the parent DV1 peptide (data not shown).
D-Peptides Are Highly Stable in Human Serum—The incorporation of D-amino acids into a peptide sequence should enhance its resistance to proteolytic degradation because unnatural residues are less likely to be recognized by natural
enzymes. To test this, the biological stability of DV1 and V1
peptides was studied in human serum. The peptides were
mixed with human serum and degraded products of peptides
monitored by HPLC for a period of time. V1 peptide was rapidly
degraded, and by 24 h the peptide peak on HPLC disappeared
completely (data not shown). In contrast, DV1 peptide did not
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FIG. 3. a and b, CXCR4 binding of peptides DV1 (䡺) and V1 (〫) as well as controls vMIP-II (●) and SDF-1␣ (Œ) as characterized by anti-CXCR4 mAb 12G5
competitive binding assay (a) and by 125ISDF-1␣ competitive binding assay (b). c,
CCR5 binding of peptides DV1 (䡺) and V1
(〫) as well as control vMIP-II (●) as characterized by 125I-MIP-1␤ competitive
binding assay.

show any degradation during the same period and even after
72 h of prolonged incubation with human serum. These results
were consistent with the notion that DV1 peptide has much
higher biological stability than V1 peptide, which should be of
advantage for any potential clinical application.
⫹
D-Peptides Inhibit HIV-1 Replication in CXCR4
Cell
Lines—Having shown that DV1 peptide is a potent CXCR4
antagonist and highly stable in biological conditions, we reasoned that it could inhibit the replication of CXCR4-dependent
HIV-1 strains by blocking the entry of viruses via CXCR4
co-receptor. By measuring CAT activity in activated human
PBMC infected with a recombinant HIV-1 containing the
HXBc2 envelope glycoproteins, we found that DV1 peptide was
a potent inhibitor of infection. By contrast, a control mutant
peptide DV1-L1A, which contains a single alanine substitution
at Leu-1 but substantially loses CXCR4 binding, did not show
any activity (Fig. 7a). The DV1 peptide was completely inactive
in control experiments measuring CAT activity in CCR5⫹CD4⫹
Cf2Th cells infected with the dual tropic 89.6 HIV-1 strain (Fig.
7b). These data are in agreement with other results described

FIG. 4. CXCR4 binding of FAM-DV1 (200 nM) competed by
SDF-1␣ (300 nM), DV1 (100 M), and V1 (100 M) on Sup T1 cells.
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FIG. 5. a, CXCR4 binding of peptides V1-DCL (Œ), V1-LCD (䡺), and DV3 (●). b, CXCR4 binding of eight DV1 mutant peptides: DV1-L1A (f),
DV1-W5A (䡺), DV1-R7A (●), DV1-K10A (E), DV1-C11A (Œ), DV1-Q16A (‚), DV1-R18A (⽧), and DV1-C11AC12 (〫). c, CXCR4 binding of peptides
DS1 (䡺) and S1 (●) derived from the N terminus of SDF-1␣. CXCR4 binding was determined by anti-CXCR4 mAb 12G5 competitive binding assay.
TABLE II
Decrease in CXCR4 binding (x-fold)

DV1
V1(28)
a

L1A

W5A

R7A

K10A

C11A

C11A, C12A

Q16A

R18A

741
29

34
4

77
65

9
⬎156

0.6 (incr)a
8 (incr)a

3
3

2
0.8 (incr)a

6
1.5

incr, the value shown is the increase in CXCR4 binding.

above and demonstrate that DV1 peptide is a selective inhibitor of HIV-1 co-receptor function of CXCR4 but not CCR5. Note
that two different cells (activated PBMC and CCR5⫹CD4⫹
Cf2Th cells) were used to test the inhibition by the peptide of
HIV-1 entry via CXCR4 and CCR5, respectively. Activated
PBMC were used because they are the most relevant target
cells for HIV-1 infection in vivo. Because activated PBMC express both CXCR4 and CCR5, we used an X4 virus, which
utilizes only CXCR4 as a coreceptor. To demonstrate that entry

of the virus is not inhibited by the peptide when CCR5 is used
as a coreceptor, one needs to switch both target cells and virus.
For this reason, we used Cf2Th cells that express CD4 and
CCR5 and can be utilized by an R5 X4 virus that uses both
CCR5 and CXCR4.
The ability of DV1 peptide to block HIV-1 replication was
also confirmed in another assay measuring the production of
viral p24 antigen in MT-4 cells after being infected with HIV-1
isolated from the supernatant of H9/IIIB cells. DV1 strongly
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FIG. 6. Intracellular calcium influx in Sup T1 cells. DV1 peptide
with the indicated concentrations and SDF-1a (100 nM) were sequentially used to treat Sup T1 cells.

inhibited p24 production as compared with control mutant
DV1-L1A (Fig. 7c). Consistent with this observation, the cell
viability assay showed that DV1 protected MT-4 cells from the
cytopathic effects of HIV-1 infection (data not shown). It was
noted that, when V1 peptide was used for comparison, it was
active during the initial period and gradually lost effect over
time, whereas DV1 peptide maintained its activity throughout
the course of experiments. This is consistent with the higher
biological stability of DV1 peptide as described above and supports the notion that peptides of D-amino acids have advantages for therapeutic application.
DISCUSSION

CXCR4 plays an essential role in many physiological functions as the receptor for chemokines such as SDF-1␣. In addition, CXCR4 is involved in the pathogenesis of HIV-1 infection
by serving as the co-receptor for the cellular entry of T and dual
tropic virus strains. CXCR4 belongs to the GPCR superfamily,
which contains a large number of membrane proteins that are
important therapeutic targets but whose structures and interactions with their ligands need to be further elucidated. In this
study, we explored the mechanism of CXCR4-ligand recognition with synthetic chemokine-derived peptides containing Damino acids in an attempt to gain insights into the structure
and function of CXCR4 and design novel inhibitors of HIV-1
entry. Through structure and function analyses of a series of
D-peptides, D- and L-hybrid peptides, and mutant analogs derived from vMIP-II and SDF-1␣, we found that the CXCR4
binding surface is tolerant of changes in peptide stereochemistry. These peptides containing some or all D-amino acids display significantly different topologies on side chains from Lcounterparts and yet retain or even enhance their highly
specific interactions with the receptor. This seems to be contrary to the notion that, in general, receptor-ligand interface is
highly sensitive to changes in stereo configurations of ligands.
ALX40 – 4C, a peptide of nine D-Arg residues, is known to

FIG. 7. Inhibition of HIV-1 replication by DV1 peptide (䡺) and
a negative control mutant DV1-L1A (Œ). a, inhibition by peptides of
CAT activity in target PBMC incubated with recombinant HIV-1 expressing CAT and containing the X4 HXBc2 envelope glycoproteins. b,
inhibition of CAT activity by peptides at 20 M in CCR5⫹CD4⫹ Cf2Th
cells infected with recombinant virus containing the envelope glycoproteins of the dual tropic 89.6 HIV-1 strain. c, inhibition of p24 production
by peptides in MT-4 cells infected with HIV-1 isolated from the supernatant of H9/IIIB cells.

bind CXCR4 (45). However, this peptide, like other highly
positively charged molecules such as T-22 (46) and AMD3100
(47), most likely acts through overall charge-charge electrostatic interactions (48). This is different from the D- and Lpeptides reported here for which specific interactions of uncharged hydrophobic side chains of the peptides with the
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receptor are clearly important. D-Peptides of same L-peptide
sequences such as DV1 described here are different from Dpeptides of reversed L-peptide sequences or so-called “retroinverso” peptides. Retro-inverso peptides can have the identical
side chain topology but opposite main chain direction as compared with L-counterparts (49). In contrast, D-peptides such as
DV1 retain the same main chain direction but adopt a distinct
side chain topology (Fig. 2). Normally, such a change in the
stereochemistry of side chains should disrupt a stereospecific
ligand-receptor interface. There are only a limited number of
cases reported in the literature where both D- and L-peptide
enantiomers recognize the same receptors, such as L- and Dpeptide ligands for calmodulin (50, 51), L- and D-peptides derived from type IV collagen that bind the ␣3␤1 integrin (52, 53),
and L- and D-peptide ligands for the co-chaperone DnaJ (Hsp40)
(54). However, to our knowledge of current literature, CXCR4
binding by D- and L-peptide ligands derived from natural chemokines as reported here is unprecedented for chemokine receptors and membrane proteins of the GPCR family. Whether
this is a unique property of CXCR4 or a similar phenomenon
can be found in other chemokine receptors or GPCRs remains
to be seen.
Our results provide surprising new insights into the biochemical nature of the CXCR4 binding surface and should
prompt further studies of the mechanism for the sterical tolerance of CXCR4-peptide interactions. More studies are needed
to characterize the detailed binding sites of D- and L-peptides on
the receptor and structural basis of D-peptide binding. Such
studies include site-directed mutations of potential receptor
residues involved in the binding of these peptide ligands and
molecular modeling of peptide-CXCR4 interaction using the
recently proposed models of CXCR4 structure (27, 28). In addition, it will be important to extend this present study of
D-peptides to modifications of full-length chemokine proteins
and examine the structure-function relationship of their interactions with the receptor. We are currently exploring these and
other related issues. Finally, it is of interest to examine
whether the observation reported here may have any implication for understanding CXCR4 interaction with HIV-1. One
may speculate that the flexibility of the CXCR4-ligand interface might be a feature of CXCR4 that HIV-1 capitalizes on.
This might allow sequence and/or conformational variation to
occur in the V3 loop, one of the gp120 components thought to
interact with CXCR4. If the resulting changes in the gp120 V3
loop are accommodated by the flexible binding surface of
CXCR4 but not that of an antibody, the virus can then evade
neutralizing antibodies although maintaining a high affinity
for the coreceptor that is necessary for viral entry into the cell.
These hypotheses as raised by the present study merit further
investigations.
The understanding of the mechanism and structural basis
for the remarkable property of the CXCR4 binding surface
described here will have important implications for the design
of novel ligands. Receptors and proteins mediating the HIV-1
entry process have become important targets for drug discovery, as agents blocking the virus from entering cells will serve
as a new type of therapeutic that augments the arsenal of
current drugs targeting the replication of the virus inside the
cell. Small molecule inhibitors of HIV-1 entry via two principal
co-receptors CXCR4 and CCR5 have been reported (32, 45– 47,
55). In addition, HIV-1 entry inhibitors have also been developed to target the HIV-1 envelope glycoprotein gp41 (56). In
this study, by taking advantage of the stability of unnatural
D-amino acids, DV1 peptide shows significant anti-HIV-1 activity in biological conditions and thus may be a desirable lead for
potential therapeutic development. As shown by this D-peptide,

the apparent lack of stereospecificity of the CXCR4 binding
surface as observed here might be exploited for the design of
other highly stable and potent ligand molecules with novel
topological features.
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